- 作者：Youngseok Lee ; Youngjoon Ryu ; Hoiseon Jeong ; Hyeyoon Chang ; Younghye Kim ; Aeree Kim ; ark@korea.ac.kr
- 关键词：HER2 ; ErbB-2 ; Fluorescence in situ hybridization ; Silver in situ hybridization ; Meta-analysis
- 刊名：Archives of Medical Research
- 出版年：2012
- 期刊代码：24_01884409
- 类别：med
- 出版时间：February, 2012
- 卷：43
- 期：2
- 页码：139-144
- 文件大小：340 K
Background and Aims
HER2 gene amplification occurs in breast cancers and has implications for treatment and prognosis. Recently, a new direct evaluation technique, silver enhanced in situ hybridization (SISH) was developed for evaluating HER2 gene status. This study was performed to evaluate the SISH technique for clinical use by comparing it to that of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC).Methods
We studied 543 cases of excised breast specimens diagnosed as invasive ductal carcinoma by IHC, FISH, and SISH using a tissue microarray. IHC, FISH, and SISH results were interpreted according to the American Society of Clinical Oncology/College of American Pathologists guidelines. A total of seven English studies that reported the concordance rates of SISH and BDISH compared to FISH published before July 2011 were retrieved.
Results
The consensus concordance rate between SISH and FISH was 96.69%(kappa value聽= 0.9175). The pooled sensitivity was 0.94 [95%confidence interval (CI)聽= 0.91-0.97], and the pooled specificity was 0.98 (95%CI聽= 0.96-099) in a meta-analysis of the retrieved studies and this study. Area under the receiver operating characteristics curve was 0.9906.
Conclusions
SISH technique is an effective modality and is comparable with FISH for evaluating HER2 gene amplification in patients with breast carcinoma.